_1579501833221.png?format=webp&height=120&width=120){kind=logo}
About Panacea Venture
Panacea Venture is a venture capital firm founded in 2017. It is primarily based out of Xuhui, China. As of Feb 2026, Panacea Venture is an active investor, having invested in 42 companies, with 1 new investment in the last 12 months. It primarily invests in Seed round in China based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series B round of KainovaTX Overall, Panacea Venture portfolio has seen 5 IPOs including key companies like Windtree Therapeutics, HanchorBio and Kindstar. A lot of funds co-invest with Panacea Venture, with names like CTI Life Sciences Fund sharing a substantial percentage of its portfolio. Panacea Venture has team of 14 people including 7 partners.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Seed & 4 more
Portfolio IPOs
Portfolio Soonicorns
Panacea Venture's List of Top Investments
Panacea Venture has a portfolio of 42 companies. Their most notable investments are in OncXerna and Actym Therapeutics.Their portfolio spans across China, United States, United Kingdom and 3 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 2 other sectors, across stages such as Series B, Seed and 4 more. Here is the list of top investments by Panacea Venture:
Provider of precision medicine, preventative health assessments, and longevity care. The company offers comprehensive health assessments to detect life-threatening conditions early. It focuses on data-driven, personalized healthcare designed to uncover health risks. The company provides services to help individuals take control of their health.
Key facts about Human Longevity
Developer of exosome-based therapeutics for severe neurological and rare diseases. It engineers exosomes to deliver gene-editing tools, proteins, and other therapeutic payloads to hard-to-reach tissues, especially the brain and central nervous system. The company is developing a pipeline of exosome-enabled medicines aimed at severe neurodegenerative, inflammatory, and rare disease indications.
Key facts about Evox Therapeutics
- Founded Year: 2016
- Location: Oxford (United Kingdom)
- Annual Revenue: £1M - £10M as on Dec 31, 2023
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $156M
- Employee Count: 50 - 199 as on Mar 01, 2026
- Investors: Redmile Group, Orbimed and 26 Others
- Latest Funding Round: Series C, Feb 16, 2021, $*****
- Highlight: Editors' Pick
Developer of GPCR‑targeted immuno‑oncology and inflammation drug candidates. It offers small molecule and antibody therapeutics targeting G protein‑coupled receptors involved in immune suppression and tumor microenvironment modulation. Its proprietary platform supports the identification and validation of novel GPCR targets. Key programs focus on oral EP4 receptor antagonists for solid tumors, Treg‑depleting anti‑CCR8 antibodies, and PAR2 negative allosteric modulators for inflammatory diseases. The pipeline emphasizes precision therapy guided by biomarker strategies, aiming to enhance immune response and address resistance mechanisms in cancer and inflammation.
Key facts about Domain Therapeutics
- Founded Year: 2008
- Location: Strasbourg (France)
- Annual Revenue: €1M - €10M as on Dec 31, 2023
- Stage: Series A
- Total Funding till date: $51.2M
- Employee Count: 36 as on Jul 31, 2026
- Investors: Kurma Partners, 3B Future Health Fund and 26 Others
- Latest Funding Round: Series A, May 10, 2022, $*****
- Highlight: Editors' Pick
4. XWPharma
XWPharma is a developer of drugs for treating neurological disorders like epilepsy, Parkinson's & others. It has developed XW10172 that is an investigational GABAB agonist that helps in the treatment of sleep disorders in Parkinson’s disease and narcolepsy. It also provides an XW10508 drug that is glutamatergic in nature and offers NMDA receptor inhibition. It helps in AMPA receptor activation for the treatment of Major depressive disorder (MDD) and chronic pain.
Key facts about XWPharma
- Founded Year: 2014
- Location: San Francisco (United States)
- Stage: Series C
- Total Funding till date: $57.5M
- Employee Count: 26 as on Jul 31, 2026
- Investors: KTB Network, Kleiner Perkins and 12 Others
- Latest Funding Round: Series C, Sep 17, 2020, $*****
- Highlight: Editors' Pick
5. OutSee
Developer of an artificial intelligence engine for predictive genomics. The AI engine predicts disease and phenotype directly from a single genome. It uncovers biological mechanisms that drive and modulate disease, rather than matching known genetic associations. The technology can find additional results after other methods have been fully exploited. It predicts complex genetics, including multi-variant effects and mechanistically cooperative interactions. This allows grouping patients in ways that other methods cannot. The predictive approach works on small and large datasets.
Key facts about OutSee
- Location: United Kingdom
- Annual Revenue: £0 - £1M as on Sep 30, 2023
- Stage: Seed
- Total Funding till date: $5.79M
- Employee Count: 10 as on Jul 31, 2026
- Investors: Ahren, Panacea Venture and 2 Others
- Latest Funding Round: Seed, Jan 13, 2026, $*****
- Highlight: Editors' Pick
Panacea Venture's Year-on-Year Investment Trends
Panacea Venture has invested in 42 companies over the last 20 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 1 investment, while as of Feb 2026, it has made 1 investment in this year. Its most recent first time investment was in KainovaTX and most recent follow-on round was in Actym Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 1 | 0 | 1 |
2024 | 2 | 0 | 2 |
2023 | 1 | 1 | 2 |
2022 | 3 | 0 | 3 |
2021 | 2 | 1 | 3 |
2020 | 4 | 0 | 4 |
2019 | 2 | 0 | 2 |
2018 | 2 | 0 | 2 |
Panacea Venture's Investments by Stage
Panacea Venture has made 6 investments in Series B stage with an average round size of $38.3M, 5 investments in Seed stage with an average round size of $37.5M and 5 investments in Series A stage with an average round size of $63.1M.Stage of entry | No. of Investments |
|---|---|
Series B | 6 |
Seed | 5 |
Series A | 5 |
Post IPO | 1 |
Series C | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Panacea Venture's Investments by Sector
Panacea Venture has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, Healthcare and HealthTech. Notably, it has invested in 32 Enterprise (B2B) companies, 31 Tech companies, 4 Software companies and at least 2 companies focusing on Saas.Sector | No. of Investments |
|---|---|
Life Sciences | 16 |
High Tech | 5 |
Enterprise Applications | 3 |
Healthcare | 3 |
HealthTech | 1 |
Others | 2 |
Note: We have considered here, only first round of investments
Panacea Venture's Investments by Geography
Panacea Venture has made most investments in China (7), followed by United States where it has made 7 investments.Country | No. of Investments |
|---|---|
China | 7 |
United States | 7 |
United Kingdom | 2 |
Canada | 1 |
France | 1 |
Note: We have considered here, only first round of investments
Panacea Venture's recent investments
Panacea Venture has made 1 investments in 2026 so far - KainovaTX.Here are the most recent investments by Panacea Venture:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Feb 10, 2026 | Canada | Series B | 9692 | [+8] | |
Jun 24, 2025 | United Kingdom | Seed | 5679 | [+2] | |
Dec 31, 2024 | - | Seed | 8772 | ||
Dec 31, 2024 | China | Seed | 8644 | [+6] | |
Oct 18, 2023 | United States | Series A | 2861 |
IPOs and Publicly Listed companies in Panacea Venture's Portfolio
5 of Panacea Venture's portfolio companies have become public. HanchorBio got listed on the Taiwan Stock Exchange (TPE), in May 2026 at marketcap of $497M and Kindstar got listed on the Hong Kong Exchanges (HKG) at marketcap of $1.14B.Here are Panacea Venture's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 29, 2026 | - | - | 6181 | |
Jul 16, 2021 | - | - | 6826 | |
Apr 29, 2021 | - | - | 6760 | |
Aug 26, 2005 | May 03, 2006 | Post IPO | 8633 | |
Aug 11, 1995 | - | - | 3155 |
Team profile of Panacea Venture
Panacea Venture has a team of 14 members including 7 Partners and 4 Venture Partners located in United States, China and 1 more location. Panacea Venture's team does not sit on the board of any company as of now.Here is a list of top team members in Panacea Venture:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Los Angeles | - | ||
Partner | Shanghai | - | ||
Partner | - | - | ||
Partner | - | - | ||
Partner | Boston | - | ||
Partner | - | - | ||
Partner | Singapore | - | ||
Venture Partner | - | - | ||
Venture Partner | - | - |
Co-investors of Panacea Venture
Over the past 20 years, 134 investors have co-invested in Panacea Venture's portfolio companies. This includes funds and angels.
- Invested before Panacea Venture: Emerging Technology Partners, Threshold and 42 others have invested in rounds before Panacea Venture. There is 1 company where Emerging Technology Partners has invested before Panacea Venture and 1 company where Threshold has invested before Panacea Venture.
- Top Co-investors of Panacea Venture: 65 investors entered a company along with Panacea Venture. These include investors like CTI Life Sciences Fund (2 companies).
- Invested after Panacea Venture: A total of 25 investors have invested in Panacea Venture's portfolio after their investments. Top Investors include Duchenne (1 company), Gates (1 company) and Orbimed (1 company).
Recent News related to Panacea Venture
•
Kainova Therapeutics Secures $32M CAD to Accelerate Therapy DevelopmentBenzinga•Feb 10, 2026•Invest Quebec, KainovaTX, Turenne Groupe, Schroders Capital and 8 others
•
OutSee Closes £2.5M Seed Funding RoundFinSMEs•Jan 13, 2026•OutSee, Empirical Ventures, Kadmos Capital, Panacea Venture and 2 others
•
OutSee secures £1.8M to advance predictive genomics drug discovery with AI platform NomalyTech Funding News•Jun 24, 2025•OutSee, Ahren, Kadmos Capital, Empirical Ventures and 1 other
•
Orange Fail Pharmaceutical Complete nearly $ 50 million Pre-A round of financingEastmoney•Jan 02, 2025•VelaVigo, Panacea Venture, Shanghai Healthcare Capital, Delian Capital and 1 other
•
•
•
BHP appoints experienced financier to lead commercial finance offerInsider Media•Jun 17, 2024•BHP, Panacea Venture
•
•
•
Venture Firm, Cancer Center Start Antibody Biotech CompanyTechnology News and Literature•Sep 08, 2023•Panacea Venture, Mariana Oncology
